Hyperlipidemia Drugs Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32

1
Global Hyperlipidemia Drugs Market Research and
Forecast Report 2024-2032

• Format PDFEXCEL

2023 IMARC All Rights Reserved
2
About IMARC Group

• International Market Analysis Research and
  Consulting Group is a leading adviser on
  management strategy and market research
  worldwide. We partner with clients in all regions
  and industry verticals to identify their
  highest-value opportunities, address their most
  critical challenges, and transform their
  businesses.
• IMARCs information products include major
  market, scientific, economic and technological
  developments for business leaders in
  pharmaceutical, industrial, and high technology
  organizations. Market forecasts and industry
  analysis for biotechnology, advanced materials,
  chemicals, food and beverage, travel and tourism,
  nanotechnology and novel processing methods are
  at the top of the companys expertise.
• IMARCs tailored approach combines unfathomable
  insight into the dynamics of companies and
  markets with close cooperation at all levels of
  the client organization. This ensures that our
  clients achieve unmatchable competitive
  advantage, build more proficient organizations,
  and secure lasting results.

3
Report Highlight and Description

• According to the latest report by IMARC Group,
  titled "Hyperlipidemia Drugs Market Global
  Industry Trends, Share, Size, Growth, Opportunity
  and Forecast 2024-2032," the global
  hyperlipidemia drugs market size reached US 22.7
  Billion in 2023.
• Hyperlipidemia refers to a condition that causes
  abnormally high levels of fats or lipids in the
  blood. It is a common type of dyslipidemia that
  can be inherited or result from an unhealthy
  lifestyle and poor diet. The disorder may lead to
  cardiac stroke, peripheral vascular diseases,
  obesity, hypertension, and cardiovascular
  disorders(CVDs). Hyperlipidemia can be detected
  by performing a blood test called a lipid panel
  or lipid profile.
• Statins are the primary line of treatment in
  secondary hyperlipidemia caused by an unhealthy
  lifestyle. Some of the other common drugs used in
  the treatment of hyperlipidemia are bile acid
  sequestrants, PCSK9, and miscellaneous
  antihyperlipidemic agents, which help reduce the
  production of cholesterol in the liver. They also
  lower the number of lipids in the bloodstream and
  reduce inflammation and damage done to the cells.
• Request for a PDF sample of this report
  https//www.imarcgroup.com/hyperlipidemia-drugs-ma
  rket/requestsample

4
Report Description

• Global Hyperlipidemia Drugs Market Trends
• The global hyperlipidemia drugs market is
  primarily driven by the increasing awareness
  regarding the associated risks of CVDs and high
  cholesterol. Governments are introducing new
  guidelines redefining at-risk patient groups and
  recommending the use of anti-hyperlipidemics to
  lower the risk of these diseases. In addition to
  this, the upcoming patent expiration has resulted
  in the genericization of statin and cholesterol
  absorption inhibitors, which is significantly
  augmenting the market growth.
• Furthermore, the launch of innovative products,
  such as the development of novel drugs, which
  offer improved efficacy and safety profile, is
  positively impacting the market across the globe.
  Moreover, there has been extensive research and
  development (RD) activities for developing
  innovative drugs.
• Looking forward, the market is anticipated to
  reach a value of US 26.8 Billion by 2032,
  exhibiting a CAGR of 1.8 during 2024-2032.
• View Report TOC, Figures and Tables
  https//www.imarcgroup.com/hyperlipidemia-drugs-ma
  rket

5
Report Segmentation

• Breakup by Drug Type
• Statins
• Bile Acid Sequestrants
• Cholesterol Absorption Inhibitors
• PCSK9 Inhibitors
• Others
• Breakup by End User
• Hospitals
• Clinics
• Others

6
Report Segmentation

• Breakup by Region
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

7
Competitive Landscape with Key Players

• Amgen Inc.
• AstraZeneca PLC
• Daiichi Sankyo Company Limited
• Eli Lilly and Company
• Esperion Therapeutics Inc.
• GlaxoSmithKline Pharmaceuticals Limited
  (GlaxoSmithKline Plc)
• Immuron Limited
• Ionis Pharmaceuticals Inc.
• Merck Co. Inc.
• Pfizer Inc.
• Sanofi S.A.

8
Key Questions Answered in the Report
9
Table of Contents

• 1    Preface2    Scope and Methodology    2.1  
   Objectives of the Study    2.2  
   Stakeholders    2.3    Data Sources       
  2.3.1    Primary Sources        2.3.2  
   Secondary Sources    2.4    Market Estimation 
        2.4.1    Bottom-Up Approach        2.4.2  
   Top-Down Approach    2.5    Forecasting
  Methodology3    Executive Summary4  
   Introduction    4.1    Overview    4.2    Key
  Industry Trends5    Global Hyperlipidemia Drugs
  Market    5.1    Market Overview    5.2  
   Market Performance    5.3    Impact of
  COVID-19  5.4    Market Forecast
• 6     Market Breakup by Drug Type    6.1  
   Statins        6.1.1 Market Trends       
  6.1.2 Market Forecast    6.2    Bile Acid
  Sequestrants        6.2.1 Market Trends       
  6.2.2 Market Forecast    6.3    Cholesterol
  Absorption Inhibitors        6.3.1 Market
  Trends        6.3.2 Market Forecast       

10
Table of Contents

•     6.4    PCSK9 Inhibitors        6.4.1 Market
  Trends        6.4.2 Market Forecast    6.5  
   Others        6.5.1 Market Trends        6.5.2
  Market Forecast7   Market Breakup by End User 
    7.1    Hospitals        7.1.1 Market Trends 
        7.1.2 Market Forecast    7.2    Clinics 
        7.2.1 Market Trends        7.2.2 Market
  Forecast    7.3    Others        7.3.1 Market
  Trends        7.3.2 Market Forecast8   Market
  Breakup by Region    8.1    North America     
    8.1.1 United States           8.1.1.1 Market
  Trends           8.1.1.2 Market Forecast       
  8.1.2 Canada           8.1.2.1 Market Trends   
         8.1.2.2 Market Forecast    8.2    Asia
  Pacific        8.2.1 China           8.2.1.1
  Market Trends           8.2.1.2 Market Forecast
• For more information, visit https//www.imarcgrou
  p.com/hyperlipidemia-drugs-market/toc

11
Disclaimer

• 2023 IMARC All Rights Reserved
• This Publication and all its contents unless
  otherwise mentioned are copyrighted in the name
  of International Market Analysis Research and
  Consulting (IMARC). No part of this publication
  may be reproduced, repackaged, redistributed or
  resold in whole or in any part. The publication
  may also not be used in any form or by and means
  graphic electronic or mechanical, including
  photocopying, recording, taping or by information
  storage or retrieval, or by any other form,
  without the express consent of International
  Market Analysis Research and Consulting (IMARC).
• Disclaimer All contents and data of this
  publication, including forecasts, data analysis
  and opinion have been based on information and
  sources believed to be accurate and reliable at
  the time of publishing. International Market
  Analysis Research and Consulting makes no
  representation of warranty of any kind as to the
  accuracy or completeness of any Information
  provided. IMARC accepts no liability whatsoever
  for any loss or damage resulting from opinion,
  errors or inaccuracies if any found this
  publication.
• IMARC, IMARC Group and Global Therapy Insight
  Series are registered trademarks of International
  Market Analysis Research and Consulting. All
  other trademarks used in this publication are
  registered trademarks of their respective
  companies.

12
Contact Us
Visit us at
https//www.imarcgroup.com
TELEPHONE [phone] E-MAIL
sales_at_imarcgroup.com